In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)

被引：0
|
作者：
Mohammad Haghighi
Leila Jahangard
Hamid Mohammad-Beigi
Hafez Bajoghli
Hassan Hafezian
Alireza Rahimi
Hamid Afshar
Edith Holsboer-Trachsler
Serge Brand
机构：
[1] Hamadan University of Medical Sciences,Research Center for Behavioral Disorders and Substances Abuse
[2] Isfahan University of Medical Sciences,Isfahan Psychosomatic Research Center
[3] Tehran University of Medical Sciences,Psychiatry and Psychology Research Center (PPRC), Roozbeh Hospital
[4] Psychiatric Hospital of the University of Basel,Center for Affective, Stress and Sleep Disorders (ZASS)
来源：
Psychopharmacology | 2013年 / 228卷
关键词：
Obsessive–compulsive disorder; Memantine; SSRIs; Double-blind trial; Placebo; Y-BOCS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：633 / 640
页数：7
相关论文
共 50 条
  • [1] In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)
    Haghighi, Mohammad
    Jahangard, Leila
    Mohammad-Beigi, Hamid
    Bajoghli, Hafez
    Hafezian, Hassan
    Rahimi, Alireza
    Afshar, Hamid
    Holsboer-Trachsler, Edith
    Brand, Serge
    PSYCHOPHARMACOLOGY, 2013, 228 (04) : 633 - 640
  • [2] Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial
    Afshar, Hamid
    Akuchekian, Shahla
    Mahaky, Behzad
    Zarean, Elham
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2014, 19 (10): : 976 - 981
  • [3] Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Sahraian, Ali
    Jahromi, Leila Razeghian
    Ghanizadeh, Ahmad
    Mowla, Arash
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (02) : 246 - 249
  • [4] Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial
    Maraone, Annalisa
    Trebbastoni, Alessandro
    Di Vita, Antonella
    D'Antonio, Fabrizia
    De Lena, Carlo
    Pasquini, Massimo
    JMIR RESEARCH PROTOCOLS, 2023, 12
  • [5] Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial
    Grant, Jon E.
    Hook, Roxanne
    Valle, Stephanie
    Chesivoir, Eve
    Chamberlain, Samuel R.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (05) : 225 - 229
  • [6] Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial
    Shalbafan, M.
    Mohammadinejad, P.
    Shariat, S. -V.
    Alavi, K.
    Zeinoddini, A.
    Salehi, M.
    Askari, N.
    Akhondzadeh, S.
    PHARMACOPSYCHIATRY, 2015, 48 (4-5) : 136 - 140
  • [7] A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder
    Hollander, E
    Kaplan, A
    Stahl, SM
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2003, 4 (01): : 30 - 34
  • [8] Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study
    Ghaleiha, Ali
    Entezari, Neda
    Modabbernia, Amirhossein
    Najand, Babak
    Askari, Neda
    Tabrizi, Mina
    Ashrafi, Mandana
    Hajiaghaee, Reza
    Akhondzadeh, Shahin
    JOURNAL OF PSYCHIATRIC RESEARCH, 2013, 47 (02) : 175 - 180
  • [9] Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial
    Sanaz Askari
    Saba Mokhtari
    Seyed Vahid Shariat
    Behnam Shariati
    Masoomeh Yarahmadi
    Mohammadreza Shalbafan
    BMC Psychiatry, 22
  • [10] Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial
    Askari, S.
    EUROPEAN PSYCHIATRY, 2023, 66 : S929 - S930
12345